Valvular & structural heart diseaseCohort study
Short-Term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice
- Prospective single-arm postmarket registry
- open-label
- multicentre
- 26 sites in Europe
- core laboratory echocardiography
Authors' conclusion
Transcatheter tricuspid valve repair was found to be safe and effective in treating significant TR in a diverse, real-world population.
Study context
- Population
- Elderly patients with severe tricuspid regurgitation (TR) and significant comorbidities, real-world setting
- Outcome
- Acute outcomes of tricuspid transcatheter edge-to-edge repair
Main finding
As reported in the abstract
Successful device implantation
99%
TR reduced to ≤moderate at 30 days
77%
Observational data: associations, not effects.
Further findings
Independent predictors of TR reduction to ≤moderate at discharge
| Comparison | OR (95% CI) | P value | |
|---|---|---|---|
| Smaller right atrial volume at baseline · baseline TR grade removed as a variable | 0.679 (0.537–0.858) | P = 0.0012 | |
| Smaller tethering distance at baseline · baseline TR grade removed as a variable | 0.722 (0.564–0.924) | P = 0.0097 | |
| 0.512Odds ratio (log scale) |
NYHA class I/II · 30 days
- NYHA class I/II, baseline to 30 days
- 20% to 79%
- P
- P < 0.0001
KCCQ score improvement · 30 days
- KCCQ score improvement (points, mean ± SD)
- 19 ± 23
- P
- P < 0.0001
Safety
Major adverse event · 30 days
- Subjects with a major adverse event at 30 days
- 14 (2.5%)
Original publication
Short-Term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice. J Am Coll Cardiol. Published 17 May 2023. doi:10.1016/j.jacc.2023.05.008
Summarised from the published abstract; every number is checked against it